Non-alcoholic fatty liver disease: a practical approach to treatment
Open Access
- 22 January 2014
- journal article
- Published by BMJ in Frontline Gastroenterology
- Vol. 5 (4), 277-286
- https://doi.org/10.1136/flgastro-2013-100404
Abstract
Non-alcoholic fatty liver disease (NAFLD) affects up to a third of the population in many developed countries. Between 10% and 30% of patients with NAFLD have non-alcoholic steatohepatitis (NASH) that can progress to cirrhosis. There are metabolic risk factors common to both NAFLD and cardiovascular disease, so patients with NASH have an increased risk of liver-related and cardiovascular death. Management of patients with NAFLD depends largely on the stage of disease, emphasising the importance of careful risk stratification. There are four main areas to focus on when thinking about management strategies in NAFLD: lifestyle modification, targeting the components of the metabolic syndrome, liver-directed pharmacotherapy for high risk patients and managing the complications of cirrhosis.Keywords
This publication has 97 references indexed in Scilit:
- Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and AdolescentsPublished by American Medical Association (AMA) ,2011
- Management of hepatocellular carcinoma: An updateHepatology, 2011
- Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary OsteoporosisCurrent Osteoporosis Reports, 2010
- A position statement on NAFLD/NASH based on the EASL 2009 special conferenceJournal of Hepatology, 2010
- Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitisHepatology, 2009
- Statins Are Associated With a Reduced Risk of Hepatocellular Carcinoma in a Large Cohort of Patients With DiabetesGastroenterology, 2009
- Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other CancersJama-Journal Of The American Medical Association, 2009
- Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosisHepatology, 2007
- Statins and cancer preventionNature Reviews Cancer, 2005
- MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancerNature, 2004